A Potential Antitumor Effect of Dendritic Cells Fused with Cancer Stem Cells in Hepatocellular Carcinoma

HCC stem cells were reported as posttreatment residual tumor cells that play a pivotal role in tumor relapse. Fusing dendritic cells (DCs) with tumor cells represents an ideal approach to effectively activate the antitumor immunity in vivo. DC/HCC stem cell vaccine provides a potential strategy to g...

Full description

Saved in:
Bibliographic Details
Published in:Stem cells international 2019-01, Vol.2019 (2019), p.1-10
Main Authors: Zhang, Xue-Hui, Luo, XiaoLing, Guo, Xing, Liang, Rong, Wu, Man-Ya, Li, Xi-Lei, Xu, Sheng, Cui, Bi-Yu, He, Jian, Pang, Ye-Bin, Feng, Yan
Format: Article
Language:English
Subjects:
Anticancer properties
Antigen (tumor-associated)
Antigens
Antitumor activity
Assaying
Biocompatibility
Cancer
Cancer vaccines
CD80 antigen
CD83 antigen
CD86 antigen
CD90 antigen
Cell culture
Cell fusion
Cell proliferation
Costimulator
Cytokines
Cytotoxicity
Dendritic cells
Development and progression
Enzyme-linked immunosorbent assay
Flow cytometry
Functional analysis
Hepatocellular carcinoma
Histocompatibility antigen HLA
Immune response
Immune system
Immunity
Immunology
Immunotherapy
Liver cancer
Lymphocytes
Lymphocytes T
Major histocompatibility complex
Medical prognosis
Medical research
Metastasis
Polyethylene glycol
Stem cells
T cells
Toxicity
Tumor cells
Tumor necrosis factor-TNF
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HCC stem cells were reported as posttreatment residual tumor cells that play a pivotal role in tumor relapse. Fusing dendritic cells (DCs) with tumor cells represents an ideal approach to effectively activate the antitumor immunity in vivo. DC/HCC stem cell vaccine provides a potential strategy to generate polyclonal immune response to multiple tumor stem cell antigens including those yet to be unidentified. To assess the potential capacity of DC/HCC stem cell vaccines against HCC, CD90+HepG2 cells were sorted from the HCC cell line HepG2. DC and CD90+HepG2 and DC and HepG2 fused cells were induced by polyethylene glycol (PEG). The influence of fusion cells on proliferation and immunological function transformation of lymphocytes was assessed by FCM and ELISA assay, respectively. The cytotoxicity assay of specific fusion cell-induced CTLs against HepG2 was conducted by CytoTox 96 Non-Radioactive Cytotoxicity Assay kit in vitro. At last, the prevention of HCC formation in vivo was described in a mouse model. The results of FCM analysis showed that the proportion of CD90+HepG2 cells in the spheral CD90+HepG2 enriched by suspension sphere culture was ranging from 98.7% to 99.5%, and 57.1% CD90+HepG2/DC fused cells were successfully constructed. The fusion cells expressed a higher level of costimulatory molecules CD80, CD83, CD86, and MHC-I and MHC-II molecules HLA-ABC and HLA-DR than did immature DCs (P
ISSN:1687-966X
1687-9678
1687-9678
DOI:10.1155/2019/5680327